Angelman Syndrome Foundation (ASF) and Dup15q Alliance proudly announce their strategic partnership to launch the LADDER Learning Network, a new medical network specifically designed for individuals with Angelman syndrome (AS) and dup15q—two rare disorders affecting the q-arm of the […]
Read more
In 2018, the ASF co-funded a feasibility study to test a newborn screening for Angelman syndrome, Prader-Willi syndrome and dup15q syndrome. As always, we thank our generous donors! Your support and belief in the ASF mission makes it possible […]
Read more
As part of a 2020 ASF funded study, Ben Philpot, PhD and Matt Judson, PhD at UNC School of Medicine have been developing a gene therapy strategy as a method to restore function of UBE3A. The early results were published […]
Read more
The Angelman Syndrome Foundation and Angelman UK announce a new partnership that will increase support to Angelman syndrome families. Angelman UK will fund eligible ASF Family Fund applicants located in the United Kingdom. Angelman UK joins the Canadian Angelman Syndrome […]
Read more
FAST, the Foundation for Angelman Syndrome Therapeutics, and ASF, the Angelman Syndrome Foundation, announce a collaboration for a legislative working group focused on furthering the awareness and treatment of Angelman syndrome through legislative advocacy. The legislative working group will continue […]
Read more
The International Angelman Syndrome Alliance (ASA) and the Angelman Syndrome Foundation (ASF) announced a newly formed joint initiative: the Global Community Advisory Board (CAB). They will work together to represent the Angelman community as a unified voice when engaging with […]
Read more
Mark Zylka, PhD and his team at UNC School of Medicine have been studying CRISPR-Cas9 as a method to unsilence the paternal copy of UBE3A. After ASF funded the project, the findings were so positive, the NIH provided additional funding of […]
Read more
On July 23, 2020, Ovid Therapeutics announced a research collaboration with UCONN Health and Stormy Chamberlain, PhD. This exciting work began as an innovative idea funded by the Angelman Syndrome Foundation. Short hairpin RNA (shRNAs) work like ASOs, but can be […]
Read more
